Literature DB >> 10739650

Induction of apoptosis by cancer chemotherapy.

S H Kaufmann1, W C Earnshaw.   

Abstract

Studies performed over the past five years have demonstrated that there are two major cell-intrinsic pathways for inducing apoptosis, one that begins with ligation of cell surface death receptors and another that involves mitochondrial release of cytochrome c. Several reports have suggested that anticancer drugs kill susceptible cells by inducing expression of death receptor ligands, especially Fas ligand (FasL). Other reports have indicated that chemotherapeutic agents trigger apoptosis by inducing release of cytochrome c from mitochondria. In this review, we describe the two prototypic death pathways, indicate experimental approaches for distinguishing whether chemotherapeutic agents trigger one pathway or the other, summarize current understanding of the role of the two pathways in chemotherapy-induced apoptosis, and discuss the implications of these studies for mechanisms of resistance to chemotherapeutic agents. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10739650     DOI: 10.1006/excr.2000.4838

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  243 in total

1.  Involvement of p38 in apoptosis-associated membrane blebbing and nuclear condensation.

Authors:  R G Deschesnes; J Huot; K Valerie; J Landry
Journal:  Mol Biol Cell       Date:  2001-06       Impact factor: 4.138

2.  Synthesis and SAR studies of novel 6,7,8-substituted 4-substituted benzyloxyquinolin-2(1H)-one derivatives for anticancer activity.

Authors:  Yi-Fong Chen; Yi-Chien Lin; Susan L Morris-Natschke; Chen-Fang Wei; Ting-Chen Shen; Hui-Yi Lin; Mei-Hua Hsu; Li-Chen Chou; Yu Zhao; Sheng-Chu Kuo; Kuo-Hsiung Lee; Li-Jiau Huang
Journal:  Br J Pharmacol       Date:  2015-01-13       Impact factor: 8.739

3.  Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer.

Authors:  Moubin Lin; David J Stewart; Margaret R Spitz; Michelle A T Hildebrandt; Charles Lu; Jie Lin; Jian Gu; Maosheng Huang; Scott M Lippman; Xifeng Wu
Journal:  Carcinogenesis       Date:  2011-04-22       Impact factor: 4.944

4.  A multimeric model for murine anti-apoptotic protein Bcl-2 and structural insights for its regulation by post-translational modification.

Authors:  Venkatarajan S Mathura; Kizhake V Soman; Tushar K Varma; Werner Braun
Journal:  J Mol Model       Date:  2003-08-30       Impact factor: 1.810

5.  Molecular imaging in oncology by means of nuclear medicine: fact or fiction?

Authors:  Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

6.  Additive antitumoral effect of interleukin-12 gene therapy and chemotherapy in the treatment of urothelial bladder cancer in vitro and in vivo.

Authors:  Wanpeng Liu; Yanwei Cao; Mario I Fernández; Haitao Niu; Youcheng Xiu
Journal:  Int Urol Nephrol       Date:  2010-11-12       Impact factor: 2.370

7.  Anticancer effects of crude extract from Melia toosendan Sieb. et Zucc on hepatocellular carcinoma in vitro and in vivo.

Authors:  Xiao-Ling Liu; Hong Wang; Ling Zhang; You-Liang Wang; Jin Wang; Peng Wang; Xiao He; Yu-Juan He
Journal:  Chin J Integr Med       Date:  2015-09-17       Impact factor: 1.978

Review 8.  Modulation of oxidative stress as an anticancer strategy.

Authors:  Chiara Gorrini; Isaac S Harris; Tak W Mak
Journal:  Nat Rev Drug Discov       Date:  2013-12       Impact factor: 84.694

9.  Side population cells from long-term passage non-small cell lung cancer cells display loss of cancer stem cell-like properties and chemoradioresistance.

Authors:  Hao Gu; Xin-Yu Wu; Rui-Tai Fan; Xin Wang; You-Zhong Guo; Rui Wang
Journal:  Oncol Lett       Date:  2016-08-02       Impact factor: 2.967

10.  Beta-irradiation used for systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in leukaemia cells.

Authors:  Claudia Friesen; Annelie Lubatschofski; Jörg Kotzerke; Inga Buchmann; Sven N Reske; Klaus-Michael Debatin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-06-26       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.